Entries by Sanne Lauriks

Second-line tisa-cel similar to standard-of-care for R/R aggressive non-Hodgkin lymphoma

The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (tisa-cel) as second-line treatment did not improve event-free survival (EFS) of patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma compared with standard-of-care [1]. These results of the phase 3 BELINDA study contradict previous CAR T-cell therapy trials that have shown improved clinical outcomes. Tisa-cel, an autologous CAR […]

/by

CAR-Hematotox score predicts toxicity, infections, and clinical outcomes in MCL

Patients with relapsed or refractory mantle cell lymphoma (MCL) and a high CAR-Hematotox score had an increased risk for haematological toxicity, infections, and an inferior progression-free survival and overall survival following treatment with brexucabtagene autoleucel (brexu-cel). According to the authors, stratifying patients for the risk of haematological toxicity may aid physicians to tailor the management of their patients. CAR T-related […]

/by

CAR-Hematotox score proves useful in relapsed/refractory MM

In patients with relapsed/refractory multiple myeloma (MM) receiving BCMA-directed CAR T-cell therapy, high CAR-Hematotox scores (HT-high) were associated with an increased risk for severe haematotoxicity, severe infections, and a reduced progression-free survival (PFS) and overall survival (OS) in this retrospective study. According to the authors, these results suggest that the CAR-Hematotox score can be used […]

/by

Promising results for novel CAR-T therapy in relapsed/refractory multiple myeloma

GC012F, a dual CAR-T therapy, showed favourable safety outcomes and a high response rate in a population of patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM) in an update of the first-in-human study testing this BCMA/CD19-targeting therapy. “FasTCAR GC012F is a CAR-T therapy that targets both BCMA and CD19 in order to establish fast, deep, […]

/0 Comments/by
,

Axi-cel more effective but tisa-cel less toxic in DLBCL

In a matched set population of patients with diffuse large B-cell lymphoma (DLBCL) who had received ≥2 lines of treatment, axicabtagene ciloleucel (axi-cel) resulted in a significantly prolonged progression-free survival (PFS) compared with tisagenlecleucel (tisa-cel). However, axi-cel was associated with significantly more frequent grade ≥3 neurotoxicity compared with tisa-cel. These results could help refine specific […]

/0 Comments/by

High rate of rapid and complete responses with axi-cel in high-risk large B-cell lymphoma

ZUMA-12 is the first study evaluating CAR T-cell therapy as part of the first-line therapy in patients with high-risk large B-cell lymphoma (LBCL), defined by the histology and/or International Prognostic Index (IPI) and by dynamic risk assessment with PET scan [1]. In this population, axi-cel demonstrated a high rate of rapid and complete responses. Patients […]

/0 Comments/by

ASCT or CAR T cell as first-line therapy for MM?

Although autologous stem cell transplant (ASCT) is still the frontline therapy for patients with multiple myeloma (MM), CAR T-cell therapies have demonstrated high efficacy rates in later treatment lines, and emerging data suggest that perhaps it should be considered for earlier lines of treatment. Prof. Salomon Manier (Lille University Hospital, France) compared the value of […]

/0 Comments/by

Next-generation cell therapies for cancer: CAR-NK cells

Dr Katy Rezvani (MD Anderson Cancer Center, TX, USA) discussed the latest research regarding the development of CAR-natural killer (NK) cell therapies for hard-to-treat cancers. Can CAR-NK cell therapies become safe and effective off-the-shelf products? “CAR T-cell therapies have resulted in a paradigm shift in our thinking of cancer treatment,” said Rezvani. “However, the currently […]

/0 Comments/by